Core Viewpoint - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange to support its internationalization strategy, with details yet to be finalized [1] Group 1: Company Overview - Chint Electric, established in August 1997, is a leading enterprise in low-voltage electrical and photovoltaic sectors in China, listed on the Shanghai Stock Exchange since 2010, with a market capitalization of approximately 63 billion yuan [1] - The company has recently terminated its plan to spin off its subsidiary, Chint Aneng, for a separate listing on the Shanghai Stock Exchange, which was initially announced at the end of 2022 and accepted in September 2023, but the application was withdrawn in September 2025 after two years of waiting [1] - Chint Electric's main subsidiaries include Tongrun Equipment, Instrumentation, and New Energy Development, with its business covering low-voltage electrical, new energy, distributed household photovoltaics, and centralized photovoltaics [1] Group 2: Financial Performance - Chint Electric's overseas asset scale has steadily increased from 12.40 billion yuan in 2023 to 15.52 billion yuan in the first half of 2025, with overseas revenue reaching 3.99 billion yuan, accounting for approximately 13.46% of total revenue [2] - The low-voltage electrical business has shown strong overseas demand, with revenue from this segment growing by 23.8% year-on-year to 3.86 billion yuan in the first three quarters of 2025, and a significant increase of 42.1% to 1.43 billion yuan in the third quarter alone [2] - For the full year of 2024, Chint Electric achieved revenue of approximately 64.52 billion yuan, a year-on-year increase of 12.70%, and a net profit attributable to shareholders of approximately 3.87 billion yuan, up 5.10% year-on-year; in the first three quarters of 2025, revenue was approximately 46.40 billion yuan, a slight decrease of 0.03%, while net profit increased by 19.49% to approximately 4.18 billion yuan [2] - As of the end of the third quarter last year, Chint Electric's total assets reached 155.15 billion yuan, with a debt-to-asset ratio of 66.09% and cash holdings of 13.54 billion yuan [2]

头部券商广发证券启动一轮规模可观的再融资，进一步为国际业务注入资本动能。 广发证券公告称，拟通过配售新增H股及发行H股可转换债券的组合方式进行融资，所募资金将全部用于向境 外子公司增资，以支持国际业务拓展。此次融资总规模预计超过60亿港元，是广发证券推进国际化战略、增强 跨境服务能力的关键一步。 近年来，随着国内资本市场双向开放深化、中资企业"走出去"需求增长，以及监管层鼓励建设一流投行，券商 加强国际业务布局已成为行业趋势。通过增资境外子公司、获取业务牌照、设立海外网点等方式，多家券商正 积极构建跨境综合金融服务能力。 双轮驱动融资，募资超60亿港元 根据公告，广发证券于2026年1月6日与配售代理及经办人分别签署协议。 此次融资采用"配售+可转债"双渠道推进：一方面，公司拟以每股18.15港元的价格，配售2.19亿股新H股，募 集资金净额预计约为39.59亿港元；另一方面，公司将发行总额为21.5亿港元的零息可转换债券，初始转换价为 每股19.82港元，债券将于2027年到期。两项融资合计募资净额预计超过60亿港元。 具体而言，广发证券以广发控股（香港）为起点，已获全球证券、投行、资产管理、财富管理等全业 ...

又一行业龙头，寻求港股上市！ 《公告》显示，为满足业务发展需要，深入推进国际化战略，积极借助国际资本市场拓宽多元融资渠道，进一步提升公司综合竞争力，正泰电器拟筹划发 行境外股份（H股）并在香港联合交易所有限公司（简称"香港联交所"）上市。 另值得关注的是，正泰居家是正泰在民用板块的核心品牌，其以泛家居领域产品及服务为核心，产品涵盖开关、照明、排插、智能锁等智能家居及泛居家 领域产品，销售覆盖线上主流电商平台与行业最密集的线下渠道经销网络，致力于成为家居电气一体化解决方案及电力行业全产业链线上线下平台服务提 供商。 此外，正泰电器还指出，本次发行H股并上市能否通过审议、备案和审核程序并最终实施具有较大不确定性。公司将依据相关法律法规的规定，根据本次 发行H股并上市的后续进展情况及时履行信息披露义务，敬请广大投资者理性投资，注意投资风险。 推广 图源 | 东方财富网 正泰电器表示，截至目前，公司正与相关中介机构就本次发行H股并上市的具体推进工作进行商讨，相关细节尚未确定。本次发行H股并上市不会导致公 司控股股东和实际控制人发生变更。 正泰集团，始创于1984年，是全球知名的智慧能源系统解决方案提供商，其深入践行" ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603091 证券简称：众鑫股份 公告编号：2026-004 浙江众鑫环保科技集团股份有限公司 关于海外孙公司对美投资 年产2万吨纸浆模塑餐具项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、对外投资概述 1、浙江众鑫环保科技集团股份有限公司（以下简称"公司"）拟通泰国众鑫环保科技有限公司（以下简 称"泰国众鑫"）在美国设立全资投资公司（以下简称"标的公司A"），并拟通过"标的公司A"在美国宾 夕法尼亚州投资年产2万吨纸浆模塑餐具项目，并以独立全资公司经营（以下简称"标的公司B"），开 展生产制造及贸易等相关业务。 2、本项目拟使用"泰国众鑫"自有资金进行投资，投资总金额预计不超过3600万美元，实际投资金额将 结合公司实际发展需要及有关政府主管部门审批（如有）批准的金额为准。公司将根据市场需求和业务 进展等具体情况分阶段实施项目建设。 3、公司于2026年01月05日召开了第二届董事会第九次会议，审议通过了《关于海外孙公司对美投资年 产2万吨纸浆模塑餐 ...

格隆汇1月6日丨德赛西威(002920.SZ)公布，为进一步推进惠州市德赛西威汽车电子股份有限公司国际 化战略布局，提升公司品牌国际影响力，加快海外业务拓展，打造国际化资本运作平台，助力公司高质 量发展，提升公司整体竞争力，德赛西威正在筹划境外发行股份（H股）并在香港联合交易所有限公司 （简称"香港联交所"）上市事项。截至目前，公司正在就本次H股发行上市的相关工作进行商讨，相关 细节尚未最终确定，本次H股发行上市不会导致公司控制权发生变化。 ...

德赛西威公告，为进一步推进惠州市德赛西威汽车电子股份有限公司国际化战略布局，提升公司品牌国 际影响力，加快海外业务拓展，打造国际化资本运作平台，助力公司高质量发展，提升公司整体竞争 力，德赛西威正在筹划境外发行股份（H股）并在香港联合交易所有限公司上市事项。 ...

智通財經APP訊，衆鑫股份(603091.SH)發佈公告，公司擬通過泰國衆鑫環保科技有限公司(簡稱"泰國衆 鑫")在美國設立全資投資公司(簡稱"標的公司A")，並擬通過"標的公司A"在美國賓夕法尼亞州投資年產 2萬噸紙漿模塑餐具項目，並以獨立全資公司經營(簡稱"標的公司B")，開展生產製造及貿易等相關業 務。該項目擬使用"泰國衆鑫"自有資金進行投資，投資總金額預計不超過3600萬美元。 本次擬對外投資，在美國設立孫公司是公司國際化戰略規劃的重要內容，更好地滿足客戶定製化需求， 有利於公司更好地服務客戶，有利於公司把握市場機遇，進而拓展公司在海外的業務規模，進一步提升 全球市場份額，提升公司在國際市場的影響力和競爭力。 ...

格隆汇1月6日丨众鑫股份(603091.SH)公布，公司于2026年01月05日召开了第二届董事会第九次会议， 审议通过了《关于海外孙公司对美投资年产2万吨纸浆模塑餐具项目的议案》。本项目拟使用"泰国众 鑫"自有资金进行投资，在美国特拉华州设立100%持股的"标的公司A"并最终在美国宾夕法尼亚州设立 项目公司"标的公司B"用于"年产2万吨纸浆模塑餐具项目"建设，投资总金额预计不超过3600万美元，实 际投资金额将结合公司实际发展需要及有关政府主管部门审批（如有）批准的金额为准。公司将根据市 场需求和业务进展等具体情况分阶段实施项目建设。 本次拟对外投资，在美国设立孙公司是公司国际化战略规划的重要内容，更好地满足客户定制化需求， 有利于公司更好地服务客户，有利于公司把握市场机遇，进而拓展公司在海外的业务规模，进一步提升 全球市场份额，提升公司在国际市场的影响力和竞争力。 ...

Core Viewpoint - The article highlights the growing strength of Chinese enterprises in international competition, emphasizing that globalization is essential for resource integration and market risk management. It focuses on Yili's recent investor day event, showcasing its achievements, innovative technologies, and future strategic plans. Group 1: Yili's Internationalization Strategy - Yili has viewed internationalization as a key development strategy since 2006, establishing a global resource, innovation, and market system under the leadership of Chairman Pan Gang [3] - The company has over 2,000 global partners across six continents and 39 countries, with 15 R&D innovation centers and 81 production bases, selling products in over 60 countries and regions [3] - Yili's international business is organized into three main systems, with a focus on regional hubs in Indonesia and Thailand, leading to significant market penetration in Southeast Asia and the Middle East [3][4] Group 2: Performance and Growth - Yili's revenue for the first three quarters of 2025 reached 90.564 billion yuan, with strong performance in overseas markets, particularly in ice cream and infant goat milk powder [4] - The company is transitioning from a focus on scale expansion to a dual emphasis on quality and growth, aiming to reshape the global dairy industry with strong Chinese influence [4] - Yili's internationalization journey is set to evolve further, with plans to move from being "Asia's first" to "the world's first" in the dairy sector under Pan Gang's leadership [4]

Core Viewpoint - Yifan Pharmaceutical has signed an exclusive agreement for the commercialization of ACT001, a first-in-class drug developed by Shangde Yaoyuan, targeting small cell lung cancer brain metastases, marking a significant step in the company's innovation and internationalization strategy [1][2]. Group 1: Agreement Details - Yifan Pharmaceutical's subsidiary, Yifan Pharmaceutical Co., will pay a total of 100 million yuan as an upfront payment, with options for either a cornerstone investment of 100 million yuan or a milestone payment of 50 million yuan, along with a tiered revenue-sharing model [1]. - The agreement covers exclusive commercialization rights in mainland China and surrounding regions, including South Korea and Southeast Asia, leveraging Yifan's existing registration and sales network in Southeast Asia [3]. Group 2: Product and Market Potential - ACT001 has received "breakthrough therapy" designation from the National Medical Products Administration and is currently in Phase III clinical trials, showing significant clinical advantages by enhancing the efficacy of chemotherapy and immunotherapy [2]. - The drug addresses a critical clinical need in the treatment of small cell lung cancer brain metastases, where existing treatment options are limited, potentially leading to improved patient outcomes [2][3]. Group 3: Strategic Implications - This collaboration is seen as a practical step for Yifan Pharmaceutical to integrate innovative products into its portfolio, enhancing its capabilities in research, production, registration, and sales [2]. - While the transaction may increase short-term expenditures, successful commercialization of ACT001 is expected to contribute to sustainable business growth and performance in the long run [3].